CANBridge Life Sciences
Suite 303A, Building E, Wangjing Pioneer Park, No.
22 articles with CANBridge Life Sciences
McCain died Saturday after deciding to discontinue treatment for brain cancer. He approached the end of his life in the same manner in which he approached me that day in Raleigh – with the strength of character.
CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
CANbridge Life Sciences, a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that the China National Drug Administration (CNDA) has approved the Investigational New Drug (IND) application for a Phase Ib/III clinical study of CAN017 in esophageal squamous cell cancer (ESCC).
AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
ND acceptance triggers $2M milestone payment from CANbridge to AVEO.
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it was granted two key patents for lead immuno-oncology candidate asunercept in multiple territories.
Dr. Orfali replaced Dr. Mark Goldberg, who was acting as interim Chief Medical Officer.
CANbridge Receives China Food and Drug Administration Approval for CAN002 as Cancer Adjuvant Therapy
CANbridge Life Sciences announced that it received an Import Medical Device Market Approval from the China Food and Drug Administration (CFDA) for CAN002 as a cancer adjuvant therapy, on April 2, 2018.
CANbridge Receives Approval to Commence CAN008 Phase II/III Trial in Glioblastoma Multiforme (GBM) in China
Multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety profiles of weekly CAN008 + re-radiation therapy (rRT) in patients with glioblastoma
2/23/2018The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) offered a negative opinion on Puma Biotechnology’s application for neratinib for breast cancer.
Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX (neratinib) in Greater China
CANbridge Life Sciences announced today that it has licensed the exclusive rights to develop and commercialize NERLYNX (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China) from Puma Biotechnology.
The position is a new one, as CANbridge ramps up its leadership in anticipation of upcoming regulatory filings expected for several of its programs
CANbridge Life Sciences Submits Investigational NDA for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) in China
CANBridge Life Sciences announced that it has submitted an IND application to the CFDA for a Phase Ib/III clinical study of CAN017 in ESCC.
CANBridge Life Sciences And AmoyDx Enter Into Strategic Partnership For CAN008 Companion Diagnostic Development
First Patient Dosed In CANBridge Life Sciences’s CAN-008 Phase I/II Trial In Newly-Diagnosed Glioblastoma Multiforme In Taiwan
CANBridge Life Sciences Signs Agreement With Boehringer Ingelheim To Manufacture Inhibitory Antibody, CAN-017, For Esophageal Squamous Cell Cancer
CANBridge Life Sciences’s CAN-008 Approved For Phase I/II Trial In Newly-Diagnosed Glioblastoma Multiforme In Taiwan